On March 2, 2015, MédiS obtained authorization to market the first human-origin recombinant alpha erythropoietin (EPO), marking a significant milestone in the Tunisian pharmaceutical industry. This achievement made MédiS the first Tunisian laboratory to produce and market its biosimilar EPO under the name EPOMAX®.